EpoCel Therapeutics is pioneering a breakthrough regenerative cell therapy for chronic kidney disease (CKD) and renal anemia. Our platform uses autologous, EPO-producing cells derived non-invasively from urine, engineered for targeted kidney regeneration.
Our lead product, represents a novel paradigm: combining regenerative cell biology with therapeutic erythropoietin production to simultaneously address inflammation, fibrosis, and anemia in CKD.
EpoCel stands for scientific excellence, translational focus, and clinical impact – aiming to bring new hope to millions of patients worldwide.
🔹 Mission
To restore kidney function and treat renal anemia through innovative, patient-derived regenerative cell therapies.
🔹 Vision
A future where chronic kidney disease is no longer a progressive sentence, but a condition treated at its root – with the patient’s own cells.
Company Details
- Address
- Inflammation
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Epocell Therapeutics Questions
Epocell Therapeutics's LinkedIn profile is https://www.linkedin.com/company/epocell-therapeutics
Epocell Therapeutics's industry is
Biotechnology Research
Epocell Therapeutics's top competitors are
Duatic,
Simon & Sterling Gmbh,
Beyond Diagnostics,
Wearefreemovers Gmbh,
Entrepreneurship Center Der Uni Bern,
Gesichtslesen Und Körpersprache,
Layered,
Analphabeta Studio,
Cellntec Advanced Cell Systems,
Gonina.
Epocell Therapeutics's categories are Biotechnology Research
